New Research Advances Cancer Immunotherapy Through Clinical Data, Resistance Mechanisms, and Microbiome Insights
New clinical data for ANKTIVA immunotherapy in lung cancer, a study on EBV-driven resistance via ADAR1 RNA editing, and research on microbiome metabolites modulating immunotherapy response were presented at major conferences and in recent publications.